JWTCR-001 is under clinical development by 2Seventy Bio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JWTCR-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JWTCR-001 overview
JWTCR-001 is under development for the treatment of solid tumors. The therapeutic candidate comprises of autologous T cells transfected with the lentiviral vector genetically modified to express enhanced T cell receptors (TCR) acts by targeting cells expressing melanoma associated antigen 4 (MAGE A4). It is being developed based on end-to-end technology platform.
2Seventy Bio overview
2Seventy Bio discovers and develops new therapies for cancer treatment. 2Seventy Bio is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of JWTCR-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
